Life Sciences & Biomedicine Science & Technology Pathology
Hepatocellular carcinoma (HCC) is the one of the leading causes of cancer mortality in the world, mainly due to the difficulty of early detection and limited therapeutic options. The implementation of HCC surveillance programs in well-defined, high-risk populations were only able to detect about 40-50% of HCC at curative stages (Barcelona Clinic Liver Cancer stages 0 & 1) due to the low sensitivities of the current screening methods. The advance of sequencing technologies has identified numerous modifications as potential candidate DNA markers for diagnosis/surveillance. Here we aim to provide an overview of the DNA alterations that result in activation of cancer pathways known to potentially drive HCC carcinogenesis and to summarize performance characteristics of each DNA marker in the periphery (blood or urine) for HCC screening.
DNA markers in molecular diagnostics for hepatocellular carcinoma
Creators
Ying-Hsiu Su - Drexel University
Selena Y. Lin - Drexel University
Wei Song - JBS Science (United States)
Surbhi Jain - JBS Science
Publication Details
Expert review of molecular diagnostics, v 14(7), pp 803-817
Publisher
Taylor & Francis
Number of pages
15
Grant note
R43 CA165312; R44 CA165312 / National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
R43CA165312 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
Resource Type
Journal article
Language
English
Academic Unit
Microbiology and Immunology
Web of Science ID
WOS:000340829200004
Scopus ID
2-s2.0-84906317471
Other Identifier
991019167645204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool: